If there is one ingredient the nutraceutical industry has underutilised relative to its clinical evidence base, it is Palmitoylethanolamide, commonly known as PEA.

PEA is not a plant extract in the traditional sense. It is an endogenous fatty acid amide, a compound the human body produces naturally that also occurs in foods including egg yolks, peanuts, and soy. First isolated in the 1950s, its clinical evidence base has expanded substantially over the past 20 years. Yet most nutraceutical manufacturers have not brought it into their formulations effectively, largely because doing so correctly requires the kind of mechanism-based thinking that defines Nutraceutical Engineering.

At Makin Laboratories, PEA is the primary active compound in three of our US patent applications: Ostizeel™ for joint health, CephaMig™ for neurological support, and PEAvision™ for eye health.

How PEA Works

PEA modulates the endocannabinoid system without directly binding to cannabinoid receptors. Its primary targets include PPAR-alpha, a nuclear receptor involved in inflammation regulation, and GPR55, involved in pain modulation. PEA also inhibits FAAH, the enzyme that degrades endogenous cannabinoids, prolonging their natural activity.

The result is a reduction of mast cell degranulation, inhibition of microglial activation, modulation of neuroinflammatory cascades, and attenuation of pain signalling throughout the body's own regulatory systems. Unlike NSAIDs, PEA does not inhibit COX enzymes. Unlike corticosteroids, it does not suppress immunity. Its tolerability profile is exceptional, and its interaction risk is low, making it particularly valuable for patients on multiple medications.

The Clinical Evidence

Over 30 clinical trials and multiple meta-analyses have examined PEA. In joint health and chronic pain, trials covering over 1,500 patients demonstrated significant reductions in pain intensity and improved functional outcomes in osteoarthritis and lower back pain, with no serious adverse events reported. In neurological applications, PEA's ability to cross the blood-brain barrier, confirmed in our CephaMig™ preclinical studies, makes it compelling for neuroinflammatory conditions. In ocular health, PEAvision™ preclinical studies demonstrated neuroprotective effects in retinal cells and antioxidant activity in ocular tissues.

The Formulation Challenge and How Makin Solved It

If PEA's evidence is strong, why is it absent from most nutraceutical products? Because formulating it correctly is genuinely difficult. PEA is inherently lipophilic; it dissolves poorly in the gastrointestinal tract, resulting in variable and often low oral bioavailability with standard powders.

Makin's solution involves micronised particle specifications, carefully selected lipid-compatible excipients, and co-formulation strategies that improve absorption and distribution. This proprietary work is a core element of what makes our three PEA-based patent applications protectable, and it is work that most nutraceutical manufacturers have not invested in.

The same molecule addresses three distinct patient problems: joint pain, neurological discomfort, and ocular health, each through a dedicated mechanism and a dedicated preclinical validation programme.

For nutraceutical brands building in these categories, Makin's licensing programme offers access to the solved formulation challenge, the surrounding patent protection, and the clinical evidence programme behind it.

Tags: PEA, Palmitoylethanolamide, Nutraceutical Engineering, Nutraceutical Formulation, Ostizeel, CephaMig, PEAvision, Joint Health, Neuroinflammation, Eye Health, Evidence-Based Nutraceutical Development